Recently, Mingche Biotechnology (Suzhou) Co., Ltd. ("Mingche Technology") announced the completion of its Series A financing, raising tens of millions of RMB. This round of financing was participated by Nanjing Innovation Investment Group, Yuanhe Holdings, Chuanggu Capital, etc. The funds raised will be used for the NMPA (National Medical Products Administration) and CE registration of the core product minimally invasive glaucoma drainage device, as well as the R&D of hydrogel drainage devices and implantable intraocular pressure sensors. At the same time, to accelerate the R&D progress of refractive myopia correction ICL (Implantable Collamer Lens) crystals, the funds will also be allocated to the R&D of ICL crystals, the construction of pilot production sites, and clinical translation projects.

In this round, Nanjing Biomedical Industry Fund and Nanjing Future Industry Angel Fund, together with Chuncheng Intelligent Manufacturing Fund under Gaochun State-owned Assets Group, jointly invested tens of millions of RMB in Mingche Technology. Yan Peng'an, General Manager of the Third Investment Department of Nanjing Innovation Investment Group, said: "The Mingche Technology project is a precise investment layout of Nanjing's '4+N' fund cluster targeting the future health track. The glaucoma field has a large patient base and urgent clinical needs, and minimally invasive glaucoma surgery (MIGS) technology is still in its infancy in China. Mingche Technology's minimally invasive glaucoma drainage device has made significant clinical progress, and has built differentiated barriers with its 'whole-eye health' product pipeline. Going forward, we will continue to link local industrial resources, follow up on the product registration process, and fully support its growth into a technology leader in the field of high-end ophthalmic devices, enabling both the improvement of medical people's livelihood and industrial upgrading."

Founded in 2021, Mingche Technology is an innovative ophthalmic medical device enterprise. Its product pipeline fully covers the minimally invasive treatment of anterior and posterior segment eye diseases. The core product pipeline includes minimally invasive glaucoma drainage (MIGS) series products, fundus retinal injection microneedles, posterior chamber phakic refractive lens (ICL) and supporting systems, and vascular interventional micro-nano robots. Currently, Mingche Technology's minimally invasive glaucoma drainage device has passed the special review procedure for Class III innovative medical devices of NMPA and entered the green channel for registration approval. The posterior chamber phakic refractive lens (ICL) and supporting systems have completed material and process finalization and are undergoing systematic verification. The vascular interventional micro-nano robot has conducted multiple rounds of large animal experiments and has won awards in national-level competitions for many times. In the future, in terms of ophthalmic product R&D, Mingche Technology will continue to focus on the innovation of ophthalmic devices featuring minimal invasiveness, intelligence, and integrated precision diagnosis and treatment, and will pay key attention to technological innovation breakthroughs in presbyopia related to population aging.